Table 4 Genes within CNV regions identified by PennCNV, cnvPartition, and ExomeDepth
Diagnosis of affected twin | Gene | Copy number (1 = deletion; 2 = duplication) | Description | Disease association (DisGeNET and DISEASES) | RVIS | pLI | %HI |
---|---|---|---|---|---|---|---|
ALS | LARGE1 | 2 | LARGE xylosyl- and glucuronyltransferase 1 | Congenital muscular dystrophy; mental retardation syndromes; | −1.11 (10.98%) | 0.96 | 4.10 |
HSP | SLC8A1 | 1 | Solute carrier family 8 member A1 | Myocardial ischaemia; status epilepticus | −1.41 (6.88%) | 0.99 | 6.09 |
Ischaemic stroke | ELOVL6 | 2 | ELOVL fatty acid elongase 6 | Heart failure; Psoriasis; obesity; atherosclerosis; atopic dermatitis | −0.27 (36.97%) | 0.97 | 3.68 |
Lactose intolerance | MBD3L2 | 2 | Methyl-CpG binding ___domain protein 3 like 2 | Stomach neoplasms | n/a | n/a | 95.74 |
ADGRE4P | 2 | Adhesion G protein-coupled receptor E4, pseudogene | Colorectal cancer | n/a | n/a | n/a | |
ADGRE1 | 2 | Adhesion G protein-coupled receptor E1 | Liver cirrhosis; secondary periodontitis | 2.21 (97.76%) | 0.00 | 90.69 | |
ASD | CD38 | 2 | CD38 molecule | Autism spectrum disorders | 0.47 (70.44%) | 0.00 | 77.57 |
Tourette’s syndrome | TOP3B | 2 | DNA topoisomerase III beta | Cognitive impairment; schizophrenia | −0.34 (33.91%) | 0.11 | 15.86 |
Tourette’s syndrome/Parkinson’s disease | NLGN1 | 2 | Neuroligin 1 | Autistic disorder; schizophrenia; bipolar disorder; depression; memory impairment | −1.26 (8.92%) | 0.76 | 1.37 |
Inclusion body myositis | AUTS2 | 2 | AUTS2, activator of transcription and developmental regulator | Neurological disorders; acute lymphoblastic leukaemia; aging of the skin; early-onset androgenetic alopecia; cancer | −1.94 (3.32%) | 1.00 | 0.51 |
LILRB3 | 2 | Leukocyte immunoglobulin like receptor B3 | Lung diseases; Takayasu’s arteritis | 0.79 (81.49%) | 0.00 | 97.17 | |
Schizophrenia | ARHGAP11B | 1 | Rho GTPase-activating protein 11B | 15q13.3 microdeletion syndrome; schizophrenia; bipolar disorder | 0.07 (52.75%) | 0.07 | 81.20 |
ARHGAP5 | 2 | Rho GTPase-activating protein 5 | Liver carcinoma; breast cancer | −1.31 (8.10%) | 0.99 | 8.15 |